{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T21:53:28Z","timestamp":1783806808949,"version":"3.55.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"13","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV continues to be a significant health concern across the world. Combination antiretroviral therapy (cART) comprising of three-drug regimens has improved clinical outcome but involves long-term toxicity concerns. Hence, to reduce drug exposure, interest in two-drug regimens has increased. This study evaluates the real-world efficacy and safety of a two-drug regimen that is a fixed-dose combination (FDC) of Dolutegravir 50\u00a0mg and Lamivudine 300\u00a0mg tablets in people living with HIV (PLHIV) in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective data included PLHIV aged \u226518 years, virally suppressed at baseline, and switched to DTG\/3TC between November 2021 and April 2022. Patients were followed for 96 weeks, with routine clinical and laboratory assessments. Virological failure was defined as viral loads &gt;1000 copies\/mL, while safety assessments tracked adverse events (AEs), weight gain, and metabolic parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 218 patients (mean age 48.08 \u00b1 10.58 yrs), 97.8% achieved virological suppression at 96 weeks with sustained virological suppression at key time points (24, 48, 72, and 96 weeks). CD4 counts improved significantly (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .002), specifically in females. Body weight increased moderately, with 16.28% experiencing \u226510% weight gain by 96 weeks. Minor statistically significant variations in cholesterol, triglycerides, and creatinine levels were observed. Nine patients discontinued DTG\/3TC due to AEs, primarily weight gain and gastrointestinal issues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study demonstrates that the DTG\/3TC FDC is an effective, safe, and well-tolerated regimen for maintaining virological suppression in real-world settings, supporting its viable use as a switching strategy in reducing drug exposure and managing long-term toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624251352064","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:04:36Z","timestamp":1750269876000},"page":"930-938","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: A retrospective study from India"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-6230","authenticated-orcid":false,"given":"Vinay","family":"Kulkarni","sequence":"first","affiliation":[{"name":"Prayas Amrita Clinic, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Parchure","sequence":"additional","affiliation":[{"name":"Prayas Amrita Clinic, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shridevi","family":"Gundu","sequence":"additional","affiliation":[{"name":"Emcure Pharmaceuticals Ltd"},{"name":"."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-6130","authenticated-orcid":false,"given":"Trupti","family":"Darak","sequence":"additional","affiliation":[{"name":"Prayas Amrita Clinic, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailas","family":"Kurkute","sequence":"additional","affiliation":[{"name":"Prayas Amrita Clinic, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Emcure Pharmaceuticals Ltd"},{"name":"."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"HIV and AIDS Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids"},{"key":"e_1_3_5_3_2","unstructured":"Understanding the HIV care continuum. 2019; Available from: https:\/\/www.cdc.gov\/hiv\/pdf\/library\/factsheets\/cdc-hiv-care-continuum.pdf"},{"key":"e_1_3_5_4_2","first-page":"75","article-title":"Modifying antiretroviral therapy in virologically suppressed HIV-1-Infected patients","volume":"76","author":"Collins SE","year":"2016","unstructured":"Collins SE, Grant PM, Shafer RW. Modifying antiretroviral therapy in virologically suppressed HIV-1-Infected patients. Drugs (Basel) 2016; 76: 75\u201398.","journal-title":"Drugs (Basel)"},{"key":"e_1_3_5_5_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2019","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2019."},{"key":"e_1_3_5_6_2","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (updated October 2018)."},{"key":"e_1_3_5_7_2","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV","year":"2019","unstructured":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. 2019. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-18.51"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir673"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v4.i2.56"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00705"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00522-7"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1"},{"key":"e_1_3_5_13_2","unstructured":"Dovato|European Medicines Agency (EMA). 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dovato"},{"issue":"11","key":"e_1_3_5_14_2","first-page":"1241","article-title":"Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults","volume":"74","author":"McCormack PL","year":"2014","unstructured":"McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs (Basel) 2014; 74(11): 1241\u20131252.","journal-title":"Drugs (Basel)"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.073189"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00100-4"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0167"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2016.07.006"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.01.21678"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211034176"},{"issue":"12","key":"e_1_3_5_25_2","first-page":"1106","article-title":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)","volume":"60","author":"AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association Chinese Center for Disease Control and Prevention","year":"2021","unstructured":"AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition). Zhonghua Nei Ke Za Zhi 2021; 60(12): 1106\u20131128.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003047"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003101"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25899"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab537"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904340"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001590"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251352064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251352064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251352064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:48Z","timestamp":1777675608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251352064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/09564624251352064"],"URL":"https:\/\/doi.org\/10.1177\/09564624251352064","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}